质子泵抑制剂奥美拉唑对氯吡格雷抗血小板效应的影响被引量：1

〗Effect of Proton Pump Inhibitors on Antiplatlet Influence of Clopidogrel

导出

摘要目的研究和探讨治疗剂量下奥美拉唑对氯吡格雷抗小板活性的影响。方法选择2009年12月—2011年1月入住内蒙古自治区人民医院心血管内科的急性冠脉综合征(ACS)病人与择期行经皮冠状动脉介入(PCI)治疗病人72例,记录基本情况,并随机分成奥美拉唑与氯吡格雷联合组(治疗组)与单用氯吡格雷组(对照组),通过流式细胞仪分别测定服药前和服药后第7天血小板P选择素阳性率。结果两组治疗前后血小板P选择素阳性率差异有统计学意义(P=0.0001)。两组间治疗前比较血小板P选择素阳性率差异无统计学意义(P=0.57),治疗后比较差异仍无统计学意义(P=0.82)。结论治疗剂量奥美拉唑短期内对氯吡格雷的抗血小板疗效无明显影响。 Objective To study the influence of omeprazole on antiplatelet aggretion of clopidogrel.Method Seventy-two patients with acute Coronary syndrome after percutaneous coronary interrvention（PCI） were randomly divided into two groups：Test group（n=42） treated with clopidogrel and omeprazole,and control group（n=30） treated with clopidogrel.All patients were treated with aspirin.The platelet P-selectin positive rate was analyzed by flow cytometry before and after treatment.Results The platelet P-selectin positive rate was significant difference between two groups after treatment for seven day（P=0.0001）.Conclusion The therapeutic dose of omeprazole has no significant effect on clopidogrel in antiplatelet effect in short period.

作者任鸿坤任志亮刘娟张国珍王玲高迎春贺文帅

机构地区内蒙古自治区人民医院

出处《中西医结合心脑血管病杂志》 2011年第11期1316-1318,共3页 Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease

基金内蒙古自治区卫生厅立项基金资助项目(No.20100097)

关键词奥美拉唑氯吡格雷急性冠脉综合征经皮冠状动脉介入 omeprazole clopidogrel acute coronary syndrome percutaneous coronary intervention

分类号 R541.4 [医药卫生—心血管疾病] R815 [医药卫生—放射医学]

引文网络
相关文献

参考文献16

1Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST- segment elevation[J]. N Engl J Med,2005,352:1179 - 1189.
2张煜.新型第3质子泵抑制剂——泮立苏[J].中国社区医师,2005,21(21):15-15. 被引量：5
3Gilard M,Arnaud B, Cornily J C, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: The randomized,double- blind OCLA (Omeprazole Clopidogrel Aspi- rin) study[J]. J Am Coll Cardiol, 2008,51 : 256 - 260.
4Si[ler - Matula ]M, Spiel AO, Laug IM, et al. Effects of panto- prazole and esomeprazole on platelet inhibition by clopidogrel[J].Am Heart J, 2009,157 : 148.
5Wenaweser P, Dorffler - Melly J, Imboden K, et al. Stent thrombo- sis is associated with an impaired response to antiplatelet therapy [J].J Am Coil Cardiol, 2005,45:1748 - 1752.
6Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump in- hibitors on the antiplatelet effects of clopidogrel[J].Thromb Hae- most,2009,101(4) :714 - 719.
7Gilard M, Arnaud B, Le GG, et al. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin[J]. J Thromb Haernost, 2006,4 : 2508 - 2509.
8Ho PM,Maddox TM,Wang L,et al. Risk of adverse outcomes as- sociated with concomitant use of clopidogrel and proton pump in- hibitors following acute coronary syndrome[J]. JAMA, 2009,301: 937 - 944.
9Juurlink DN, Gomes T, Ko DT, et al. A population - based study of the drug interaction between proton pump inhibitors and elopi- dogrel[J]. CMAJ, 2009,180 : 713 - 718.
10Kim KA,Park PW,Hong SJ,et al. The effect of CYP2C19 poly- morphism on the pharmacokinetics and pharmacodynamics of clo- pidogrel: A possible mechanism for clopidogrel resistance[J]. Clin Pharmacol Ther, 2008,84 : 236 - 242.

二级参考文献13

1韩雅玲,王耿,荆全民,王守力,王祖禄,王冬梅,马颖艳,栾波.急性冠状动脉综合征介入治疗4670例近期疗效的评价[J].中华医学杂志,2005,85(15):1040-1044. 被引量：45
2[1]Okabe S,Amagase K.An overview of acetic acid ulcer models-the history and state of the art of peptic ulcer research.Biol Pharm Bull,2005,28(8):1321-1341.
3Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel [J] .CMAJ, 2009, 180 (7): 713-718.
4Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome [ J ] . JAMA, 2009, 301 ( 9 ) : 937-944.
5Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel [ J ] . Thromb Haemost, 2009, 101 (4) : 714-719.
6Mehta SR, Yusuf S, Peters R J, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention : the PCI-CURE study [ J ] . Lancet, 2001, 358 (9281) : 527-533.
7Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin : meta-analysis [ J ] . BMJ, 2000, 321 ( 7270 ): 1183-1187.
8O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacody- namic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor : an analysis of two randomised trials [ J ] . Lancet, 2009, 374 ( 9694 ) : 989-997.
9O'Donoghue M, Antman EM, Braunwald E, et al. The efficacy and safety of prasugrel with and without a glycoprotein Ⅱb/Ⅲa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention : a TRITON-TIMI 38(Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis [ J ] . J Am Coil Cardiol, 2009, 54 ( 8 ) : 678-685.
10Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrd [ J ] . Thromb Haemost, 2000, 84 (5) : 891.